hit counter
Alkermes plc (ALKS) Stock News Sentiment & Price - Sentifly
ALKS - Sentifly



Your watchlist is empty. Go add some tickers to it!

Alkermes plc (ALKS)

ALKS Price and Sentiment
Positive, Negative
Loading chart...
ALKS Latest news
Alkermes Announces First Subject Dosed in Phase 1 Study of ALKS 1140 for the Treatment of Neurodegenerative and Neurological Disorders
2021-11-11 07:00

DUBLIN, Nov. 11, 2021 /PRNewswire/ --  Alkermes plc (Nasdaq: ALKS) today announced dosing of the first subject in a phase 1 study evaluating the safety and tolerability of ALKS 1140 in healthy adults. ALKS 1140 is a novel, investigational CoREST-selective (co-repressor of repressor element-1 silencing transcription factor) HDAC (histone deacetylase) inhibitor candidate for the treatment of neurodegenerative and neurological disorders.

Zacks Investment Research
Down 21.4% in 4 Weeks, Here's Why You Should You Buy the Dip in Alkermes (ALKS)
2021-11-10 11:28

Alkermes (ALKS) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Alkermes to Take Part in the Stifel Virtual Healthcare Conference
2021-11-09 16:00

DUBLIN, Nov. 9, 2021 /PRNewswire/ --  Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a fireside chat at the Stifel Virtual Healthcare Conference on Tuesday, Nov. 16, 2021 at 9:20 a.m. ET (2:20 p.m.

The Motley Fool
Why Alkermes Stock Is Sinking Today
2021-11-09 11:36

Johnson & Johnson partly ended two licensing agreements with the company.

Alkermes Announces Receipt of Notices of Partial Termination From Janssen Pharmaceutica
2021-11-08 16:05

DUBLIN, Nov. 8, 2021 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that it received notices of partial termination (the "Notices") in respect of two license agreements with Janssen Pharmaceutica N.V. ("Janssen"), a subsidiary of Johnson & Johnson and, under these agreements, a licensee and recipient of Alkermes' nanoparticulate formulation technology, known as NanoCrystal® technology.

Alkermes to Present Data on Nemvaleukin Alfa at the Society for Immunotherapy of Cancer's (SITC) 36th Annual Meeting
2021-11-03 07:00

DUBLIN, Nov. 3, 2021 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced plans to present a poster related to nemvaleukin alfa (nemvaleukin), the company's novel, investigational, engineered interleukin-2 (IL-2) variant immunotherapy, at the Society for Immunotherapy of Cancer's (SITC) 36th Annual Meeting, taking place Nov. 10-14, 2021. The poster will include data from the ION-01 study, a phase 2 trial evaluating intravenous nemvaleukin in combination with pembrolizumab in patients with recurrent or metastatic head and neck squamous cell carcinoma that had previously progressed on an anti-PD-(L)1 therapy.

7 A-Rated Healthcare Stocks to Buy for the Long Haul
2021-11-01 11:26

It looks like we're on the back end of the Covid pandemic, so it's a good time to look at healthcare stocks that have a big future. The post 7 A-Rated Healthcare Stocks to Buy for the Long Haul appeared first on InvestorPlace.

Zacks Investment Research
Alkermes (ALKS) Q3 Earnings Beat Estimates, Revenues Miss
2021-10-28 13:45

Alkermes' (ALKS) earnings in the third quarter of 2021 beat estimates while revenues miss the same. The company reiterates financial guidance for the ongoing year.

Seeking Alpha
Alkermes plc. (ALKS) CEO Richard Pops on Q3 2021 Results - Earnings Call Transcript
2021-10-27 14:38

Alkermes plc. (ALKS) CEO Richard Pops on Q3 2021 Results - Earnings Call Transcript

Why Are Alkermes Shares Trading Lower Today?
2021-10-27 12:00

Alkermes plc (NASDAQ: ALKS) posted Q3 sales of $294.1 million, up 11% Y/Y, missing the consensus of $301.36 million.  Vivitrol sales increased 11% to $88.8 million, and Aristada sales increased 10% to $68.9 million.

Loading more news...